1. Medtech Insight
  2. >>Archive

Lifecore's Hapset plaster cleared for further use:

Lifecore Biomedical's hydroxylapatite bone graft plaster, Hapset, has been cleared for use in defect restorations in maxillary, mandibular and zygomatic sites. Hapset is currently cleared by the US FDA for use only in the restoration of periodontal and extraction socket bone defects in dental surgery. The company based in Chaska, Minnesota, estimates that approximately 430,000 maxillofacial bone repair procedures are performed annually in the US.

Lifecore Biomedical's hydroxylapatite bone graft plaster, Hapset, has been cleared for use in defect restorations in maxillary, mandibular and zygomatic sites. Hapset is currently cleared by the US FDA for use only in the restoration of periodontal and extraction socket bone defects in dental surgery. The company based in Chaska, Minnesota, estimates that approximately 430,000 maxillofacial bone repair procedures are performed annually in the US.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

GE HealthCare Halves 2025 Tariff EPS Hit As Global Supply Chain Realigns

 
• By Shubham Singh

For the third quarter of 2025, GE HealthCare projects year-over-year organic revenue growth in the range of 2%-3%. However, adjusted EPS is expected to decline in the high single digits year-over-year, reflecting the ongoing effect of tariff costs.

Roberts’ Departure At NICE Sparks Hunt For New CEO

 
• By Ashley Yeo

Healthtechs are reflecting on the resignation of Sam Roberts as chief executive of NICE and how medtech assessment program changes underway at the England and Wales HTA body might be impacted.

Inspection Readiness 101: Be Prepared To Avoid Common Pitfalls When The FDA Comes Knocking

 
• By Brian Bossetta

A panel of regulatory pros offered stakeholders tips for avoiding FDA citations after facility inspections. The July 29 webinar, hosted by ProPharma and Hyman Phelps and McNamara, follows the agency’s May announcement that it plans to up random foreign inspections.